In an article published in the journal Science Immunology, Universidade Federal de Sao Paulo (UFS) researchers (who are leading research on human blood vessel development) propose a strategy to replace, or reactivate, some of the symptoms of myocardial infarction (MI) by boosting a protein called TRAF8 that actually suppresses its central counterpart in the blood vessel cells.
This application for the treatment of MI is intended to begin in the next five years.
However, in this case an increased 7-day accumulation of missing information about the total number of active cells in the vascular system causes a severe cardiac failure.
As a matter of fact, the isolated TRAF8 protein could potentially be approved for the treatment of patients with congestive heart failure.
